Editas Medicine Announces Scientific Multi-Year Collaboration with Fondazione Telethon and Ospedale San Raffaele
-Company to Collaborate with Leading Genomic Medicines Institutes to Progress Genome Edited Hematopoietic Stem Cell and T Cell Based Therapies-
"Dr. Naldini and SR-TIGET are world leaders in gene therapy. They have pioneered many important scientific advancements working with cells of the immune system and have extensive expertise in translating that work into cell-based therapies," said
"My team and I believe genome editing is a promising answer to advance medicines to treat technically challenging diseases," said Dr. Naldini. "We at
The goal of the three-year research collaboration includes the development of gene correction strategies for the treatment of rare diseases, including two specified indications in the blood and bone marrow. This collaboration is part of Editas Medicine's overall HSC and T cell editing product development strategy for challenging disease areas.
About
About Fondazione Telethon
Fondazione Telethon is a major biomedical charity in
About Ospedale San Raffaele
Ospedale San Raffaele (OSR) is a clinical-research-university hospital established in 1971 to provide international-level specialised care for the most complex and difficult health conditions. Since 2012 OSR is part of Gruppo Ospedaliero San Donato, the leading hospital group in
About
Settled in
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's Quarterly Report on Form 10-Q, which is on file with the
Media ContactDan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor ContactJesse Baumgartner
Stern Investor Relations, Inc.
(212) 362-1200
jesse@sternir.com